Arcus Biosciences, Inc. (RCUS) financial statements (2020 and earlier)

Company profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments587976687175170
Cash and cash equivalents587976687175170
Receivables  0 000
Contract with customer, asset05   5 
Other undisclosed current assets13511615217718818597
Total current assets:193200228245259265267
Noncurrent Assets
Property, plant and equipment9101011111213
Long-term investments and receivables  01122
Long-term investments  01122
Restricted cash and investments0000000
Other noncurrent assets1000000
Other undisclosed noncurrent assets 6 13812
Total noncurrent assets:10161114162126
TOTAL ASSETS:203217239259275287294
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities141318109910
Accounts payable5323325
Accrued liabilities1010168674
Deferred revenue77  
Contract with customer, liability77   
Other liabilities1122222
Other undisclosed current liabilities    665
Total current liabilities:23212719171716
Noncurrent Liabilities
Liabilities, other than long-term debt17191618667
Deferred revenue1214  
Contract with customer, liability1112   
Deferred rent credit4444445
Other liabilities1112222
Other undisclosed noncurrent liabilities    171916
Total noncurrent liabilities:17191618232523
Total liabilities:39404237404239
Stockholders' equity
Stockholders' equity attributable to parent164177197222235245255
Common stock0000000
Additional paid in capital369366363360358356354
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(205)(189)(166)(138)(123)(111)(100)
Total stockholders' equity:164177197222235245255
TOTAL LIABILITIES AND EQUITY:203217239259275287294

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:10222241
Operating expenses(27)(25)(31)(21)(15)(16)(17)
Operating loss:(18)(23)(29)(19)(13)(12)(16)
Nonoperating income1111112
Loss from continuing operations before equity method investments, income taxes:(17)(22)(28)(18)(12)(11)(14)
Income from equity method investments    1  
Loss before gain (loss) on sale of properties:(17)(22)(28)(18)(12)(11)(14)
Other undisclosed net loss    (1)  
Net loss available to common stockholders, diluted:(17)(22)(28)(18)(12)(11)(14)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(17)(22)(28)(18)(12)(11)(14)
Other comprehensive income (loss) (0)00   
Other undisclosed comprehensive income (loss)0   (0)  
Comprehensive loss:(16)(22)(28)(18)(12)(11)(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0  0(0)0
Comprehensive loss, net of tax, attributable to parent:(17)(22)(28)(18)(12)(11)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: